InflaRx (IFRX) Common Equity (2022 - 2025)

InflaRx (IFRX) has disclosed Common Equity for 4 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 87.28% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2025, down 87.28% year-over-year, with the annual reading at $8.3 million for FY2025, 87.28% down from the prior year.
  • Common Equity hit $8.3 million in Q4 2025 for InflaRx, down from $65.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $110.4 million in Q4 2023 to a low of $8.3 million in Q4 2025.
  • Historically, Common Equity has averaged $68.6 million across 4 years, with a median of $77.9 million in 2022.
  • Biggest five-year swings in Common Equity: grew 22.45% in 2023 and later plummeted 87.28% in 2025.
  • Year by year, Common Equity stood at $90.1 million in 2022, then increased by 22.45% to $110.4 million in 2023, then plummeted by 40.54% to $65.6 million in 2024, then tumbled by 87.28% to $8.3 million in 2025.
  • Business Quant data shows Common Equity for IFRX at $8.3 million in Q4 2025, $65.6 million in Q4 2024, and $110.4 million in Q4 2023.